Investigational CagriSema produced 23.1% to 26.7% weight loss across menopause stages at 68 weeks, with improvements in cardiometabolic risk factors.
|Slideshows|February 15, 2019
Estradiol Levels Predict Fracture Risk During the Menopausal Transition
Author(s)Gregory M. Weiss, MD
Authors of a new study found that estradiol levels can be used to predict fracture risk among women during the menopausal transition.
Advertisement
Advertisement
Related to this article
TMS 2026: Nearly 67% of US women receiving elinzanetant achieved at least a 50% reduction in menopausal VMS frequency by week 12 in pooled phase 3 trial data.
TMS 2026: Only 21.7% of women initiated menopause hormone therapy, with significant racial disparities and low treatment persistence, a new study finds.
TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.
JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for menopausal vasomotor symptoms.
TMS 2026: Women exercising at least 5 days a week reported lower perimenopause symptom scores across psychological, somatic, and urogenital domains.
TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.
Hormone Therapy Linked to More Frequent Migraines, but Not Greater Severity, in Postmenopausal Women
TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.
Advertisement
Advertisement
Trending on Patient Care Online
1
What the CLARITY Study Means for Counseling on Long-Acting HIV PrEP
2
CagriSema Cuts Weight Up to 27% Across Menopause Stages: TMS 2026
3
Implementing Long-Acting HIV PrEP: Clinic and Pharmacy Infrastructure
4
3 Questions Primary Care Physicians Should Ask About Menopause Symptoms, With Stephanie Faubion, MD
5